Literature DB >> 8957991

Isoflurane for sedation in a case of congenital myasthenia gravis.

C McBeth1, T G Watkins.   

Abstract

We describe the use of isoflurane for the management of a 3-yr-old boy with congenital myasthenia gravis who required ventilation for pneumonia. While in the intensive care unit he was sedated with isoflurane for 5 days (81 MAC-h). This provided a safe, easily controllable method of sedation which avoided the use of neuromuscular blocking agents and appeared to have no significant side effects during use. However, after it was stopped the patient developed a fine, self-limiting tremor which lasted for 2 days. Previous reports of paediatric patients sedated with isoflurane suggest that prolonged exposure may result in temporary dose-dependent neurological dysfunction, including hallucinations, ataxia and non-purposeful movements.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8957991     DOI: 10.1093/bja/77.5.672

Source DB:  PubMed          Journal:  Br J Anaesth        ISSN: 0007-0912            Impact factor:   9.166


  3 in total

1.  [AnaConDa].

Authors:  C Sirtl; H Laubenthal; A Meiser
Journal:  Anaesthesist       Date:  2007-12       Impact factor: 1.041

2.  Isoflurane decreases proliferation and differentiation, but none of the effects persist in human embryonic stem cell-derived neural progenitor cells.

Authors:  Hye-Min Sohn; Hye Young Kim; Seongjoo Park; Sung-Hee Han; Jin-Hee Kim
Journal:  J Anesth       Date:  2016-11-05       Impact factor: 2.078

3.  General anesthesia for treating scoliosis with congenital myasthenia syndrome: a case report.

Authors:  Atsushi Yamashita; Yuka Muramatsu; Hiromi Matsuda; Hirotsugu Okamoto
Journal:  JA Clin Rep       Date:  2022-08-31
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.